Lilly Humatrope Short Stature Prescribing Criteria Recommended By Cmte.
Executive Summary
Lilly should develop prescribing criteria to guide the use of Humatrope for non-growth hormone deficient short stature in pediatric patients, members of FDA's Endocrinologic & Metabolic Drugs Advisory Committee suggested during a June 10 meeting
You may also be interested in...
Humatrope And Human Enhancement: Lilly Drug Featured In Bioethics Report
FDA's approval of Humatrope for idiopathic short stature plays a prominent role in a report by the President's Council on Bioethics as an example of the blurry line between medical need and human enhancement
Humatrope And Human Enhancement: Lilly Drug Featured In Bioethics Report
FDA's approval of Humatrope for idiopathic short stature plays a prominent role in a report by the President's Council on Bioethics as an example of the blurry line between medical need and human enhancement
Lilly Humatrope Postmarket Plans: Voluntary Study, No Patient Registry
An assessment of the long-term safety and efficacy of Lilly's Humatrope for idiopathic short stature will rely on a voluntary ongoing postmarket research program